Search

everythinglearnresearchcommunity

for

Search:↓

3aHSD enzyme's role in hair loss and a crowdfund for research. Goal: explore new treatments, study RU58841, and develop natural topical product.

Creatine may cause hair shedding and texture changes, with mixed user experiences. Combining creatine with finasteride doesn't always prevent these effects, possibly due to individual DHT sensitivity.

A user experienced initial side effects from finasteride, including erectile dysfunction and emotional changes, but later noticed increased muscle mass and assertiveness. Hormonal tests showed elevated estrogen and prolactin levels, which slightly decreased over time; the user plans lifestyle changes to see if they help.

A 33-year-old male is experiencing thinning at the temples and hairline, with increased shedding over the past year. The user suspects androgenetic alopecia (AGA) despite AI suggesting a maturing hairline.

The user has high DHT levels despite using dutasteride, which may not be effective due to potential damage or spoilage. They are considering a hair transplant if DHT levels don't decrease after two years.

The post discusses the user's experience with hair loss treatment RU58841, which was tested for quality and found to be 96+% pure. The conversation includes various responses, with some users questioning the safety of the product and others expressing satisfaction with the test results.

The conversation discusses the potential effectiveness and future results of the hair loss treatment pp405, with questions about its impact on different hair loss stages and areas. There is anticipation for phase 3 trial results to provide more data, and hope that pp405 could enhance hair transplant outcomes.

A 21-year-old male with a thyroid condition noticed his hair thinning uniformly without a receding hairline. He is considering using a 5ARI to prevent further baldness if he starts TRT.

A humorous discussion about hair regrowth using finasteride, with jokes about telekinesis and tiny ants. The conversation is satirical, with users making light of hair loss treatments.

A user shares progress on hair thickening using finasteride, minoxidil, RU58841, and dermastamping. Another user notes slow but ongoing improvement with a similar treatment routine.

OP used 1mg finasteride for 4 years, then had a hair transplant, and for the past 6 months has been using 0.5mg dutasteride and 2.5mg oral minoxidil twice daily. The treatments resulted in significant hair density and thickness improvement.

The user shared their personal experience with hair loss, hormone imbalances, and treatments including testosterone boosters, natural estrogen blockers, and DHEA. They suggest that low-dose finasteride and natural hormone therapy could reduce hair loss with fewer side effects.

The FDA will now require only one clinical trial for drug approval, potentially speeding up the release of hair loss treatments like PP405. Pelage is expected to present full results of PP405 Phase 2a trials and move to Phase III in mid-2026.

A user shared their success in getting a prescription for 0.1% Alfatradiol, a topical treatment for hair loss similar to finasteride but with fewer side effects. They found a pharmacy to compound it and will update on the results.

After 4 months of using topical finasteride and minoxidil, blood tests showed increased E2, Test, and Prolactine levels. The user is concerned about potential side effects like gyno and is seeking advice on managing these values.

A 21-year-old shared impressive hair regrowth results after nearly three years using 1mg finasteride and 2.5mg oral minoxidil daily. The user experienced shedding periods but reported no side effects, and the transformation was praised by many.

The conversation is about managing allopregnanolone deficiency caused by 5-alpha-reductase inhibitors like finasteride or dutasteride. Specific treatments discussed for hair loss include Minoxidil, finasteride, and RU58841.

People are discussing their reactions if PP405 fails in phase 3 trials, with some expressing skepticism and others holding onto hope for future treatments like GT20029 and Breezula. Many mention continuing with existing treatments like minoxidil and finasteride, while others express disappointment and consider alternative solutions.

The conversation is about using a DHT-blocking supplement alongside finasteride for hair loss. The user decided against the supplement and increased their finasteride dose from 1 mg to 2.5 mg per day.

A user proposed genetically engineering scalp stem cells to stop androgen receptors from causing hair loss. Others discussed the feasibility, existing research, and potential issues with this approach, including targeting the correct cells and unintended effects.

Bryan Johnson used a customized hair restoration formula from Roots byGA, which includes Minoxidil, Cetirizine HCl, Latanoprost, Dutasteride, Melatonin, Caffeine, Tretinoin, Vitamin D3, and Vitamin E. Many users are skeptical of the effectiveness and uniqueness of the treatment, suggesting that standard treatments like Minoxidil and Dutasteride are more reliable.

A user reported significant hair improvement using ginseng oil along with Minoxidil, finasteride, RU58841, and microneedling, leading them to cancel a hair transplant. Other users requested more details and proof.

The user has been using finasteride and minoxidil for nearly three years, maintaining and possibly regrowing hair despite noticing shedding and miniaturized hairs. They are considering adding another treatment due to concerns about ongoing hair loss.

New hair loss treatments like GT20029, Clascoterone, and PP405 are being discussed, with concerns about how to apply multiple topicals alongside existing treatments like minoxidil and finasteride. Suggestions include creating a routine, mixing treatments, or minimizing redundancy in treatment stacks.

The user shared their bloodwork results showing DHT at 17 ng/dl and testosterone at 287 ng/dl, with a slight Vitamin D deficiency. They are seeking opinions on these levels and have an upcoming dermatologist appointment.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

Combining finasteride with minoxidil and tretinoin is discussed, with concerns about potential overdose. It is suggested that high doses of finasteride do not provide additional benefits beyond 1 mg.

There are no updates on GT20029, and concerns about its safety and effectiveness remain. The phase III trial has not started, and there are no new studies or data releases.

PP405 shows potential for hair growth by increasing terminal hair and converting vellus hairs, but results are modest and more waiting is needed. It complements existing treatments like minoxidil and finasteride, but won't replace them.

A user is considering mixing Stemoxydine, RU-58841, Alfatradiol, and Tretinoin into a single topical solution for hair loss. They are concerned about potential interactions that could reduce the effectiveness of these ingredients.